@Treed and @Bazsa
Re "Not sure where you got this from,
"works in a 40% subset of adults."
This came from Michael Schuster a couple of years ago, listen here. Elsewhere, adult treatment was not given approval in NZ and Canada, but is available in Japan, although I am not sure how the treatments are going there
"Still a very good result" .. maybe, however the comment Mr Schuster made was that the treatment still needs to be trialled and proven in adults, so it is not clear what he meant by "works". Anyway, I am not critical of the progress the company have made with this nasty disease, I am simply commenting on @roka 's observation about why the market has not reacted more enthusiastically.
Ann: Key Day 100 Survival Results In P3 GvHD Trial, page-94
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |